PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targeted p185erbB2/neu Tumor ImmunotherapyYasuhiro Nagai, Mark I. Greene, Yukinori Tanaka et al.|Frontiers in Immunology|2019Cited by 73
PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC).Xuewei Ding, Han Liang, Xuejun Wang et al.|Journal of Clinical Oncology|2023Cited by 30